Results 181 to 190 of about 1,203 (200)
Some of the next articles are maybe not open access.
An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date
Expert Opinion on Pharmacotherapy, 2021Invasive fungal infections, especially candidemia and invasive candidiasis, cause significant morbidity and mortality. The epidemiology of candida infections have changed dramatically due to an increase in risk factors associated with the development of infection and the emergence of resistant isolates such as C. glabrata and C. auris.
Rhonda E, Colombo, Jose A, Vazquez
openaire +2 more sources
Obstetrics & Gynecology, 2022
INTRODUCTION: Ibrexafungerp, a novel one-day oral triterpenoid antifungal, was recently approved for the treatment of vulvovaginal candidiasis (VVC). Ibrexafungerp is a fungicidal with broad activity against Candida species, including fluconazole-resistant strains.
Oluwatosin Goje +3 more
openaire +1 more source
INTRODUCTION: Ibrexafungerp, a novel one-day oral triterpenoid antifungal, was recently approved for the treatment of vulvovaginal candidiasis (VVC). Ibrexafungerp is a fungicidal with broad activity against Candida species, including fluconazole-resistant strains.
Oluwatosin Goje +3 more
openaire +1 more source
Obstetrics & Gynecology, 2019
INTRODUCTION: The treatment of fungal infections, like Vulvovaginal Candidiasis (VVC), during pregnancy is difficult due to the teratogenicity associated with existing anti-fungal treatment options. VVC, also known as yeast infection, is especially common during pregnancy. Fluconazole, the oral standard of care, is not approved
Christina Carruthers +5 more
openaire +1 more source
INTRODUCTION: The treatment of fungal infections, like Vulvovaginal Candidiasis (VVC), during pregnancy is difficult due to the teratogenicity associated with existing anti-fungal treatment options. VVC, also known as yeast infection, is especially common during pregnancy. Fluconazole, the oral standard of care, is not approved
Christina Carruthers +5 more
openaire +1 more source
Obstetrics & Gynecology, 2019
INTRODUCTION: Vulvovaginal candidiasis (VVC) is a common fungal infection caused by Candida spp., with only one oral treatment, fluconazole, currently approved in the U.S. Another oral option is desirable, particularly with azole resistance on the rise among some Candida spp.
Katyna Borroto-Esoda +3 more
openaire +1 more source
INTRODUCTION: Vulvovaginal candidiasis (VVC) is a common fungal infection caused by Candida spp., with only one oral treatment, fluconazole, currently approved in the U.S. Another oral option is desirable, particularly with azole resistance on the rise among some Candida spp.
Katyna Borroto-Esoda +3 more
openaire +1 more source
Obstetrics & Gynecology, 2019
INTRODUCTION: Ibrexafungerp (IBX, formerly SCY-078) is a novel IV/oral antifungal currently in development for the treatment of invasive and mucocutaneous fungal infections. IBX has broad activity against Candida spp., including azole-resistant strains.
Rebecca Cadet +3 more
openaire +1 more source
INTRODUCTION: Ibrexafungerp (IBX, formerly SCY-078) is a novel IV/oral antifungal currently in development for the treatment of invasive and mucocutaneous fungal infections. IBX has broad activity against Candida spp., including azole-resistant strains.
Rebecca Cadet +3 more
openaire +1 more source
Antimicrobial Agents and Chemotherapy
ABSTRACT Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti- Candida activity.
Alexander Maximilian Aldejohann +5 more
openaire +2 more sources
ABSTRACT Invasive candidiasis is a major hospital-acquired infection. Usually, echinocandins are considered first-line treatment. However, resistant phenotypes have emerged. Ibrexafungerp (IBX) is a new antifungal substance with potent anti- Candida activity.
Alexander Maximilian Aldejohann +5 more
openaire +2 more sources
Ibrexafungerp to treat acute vulvovaginal candidiasis
Nature Reviews Urology, 2021openaire +2 more sources
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
Clinical Infectious Diseases, 2022Paul R Nyirjesy, Jack D Sobel
exaly